Home / Expertise / Intellectual Property
cut away of nautilus shell showing the beautiful spiral inside

Intellectual Property

International

In today’s knowledge economy, a large part of the value of your business is based on intangible assets and goodwill. Your intellectual property plays a key role in obtaining a competitive advantage. A cohesive IP strategy, including both commercialisation and enforcement, will ensure you get maximum value from your portfolio. With 150 specialist lawyers in 33 countries, we understand your business needs and have worked with some of the best-known brands, from banks to tech and media companies, pharmaceuticals and FMCG companies. This industry-specific approach can help you realise your commercial goals.

The right brands will win the hearts and minds of your customers. The right patents will prevent others exploiting your ideas or provide a substantial barrier to market access. Copyright, know-how and designs also play a vital role. We focus on key sectors relevant to you such as lifesciences, automotive, machinery, manufacturing, consumer products, financial services and TMC. This means you get in-depth industry knowledge as well as legal expertise for the protection of your IP. If you are involved in a dispute, we can guide you through the litigation process.

Read more Read less
June 2019
CMS In­tel­lec­tu­al Prop­erty Glob­al Bro­chure
In today’s know­ledge eco­nomy, a large part of the value of your busi­ness de­pends on in­tan­gible as­sets and good­will. Your in­tel­lec­tu­al prop­erty (IP) plays a key role in gain­ing and keep­ing your com­pet­it­ive edge.
Our In­ter­na­tion­al In­tel­lec­tu­al Prop­erty Group
In­tel­lec­tu­al Prop­erty (IP) rep­res­ents one of the most im­port­ant re­sources a com­pany can have, and CMS helps cli­ents to se­cure and pro­tect such stra­tegic as­sets. CMS has more than 150 at­tor­neys who spe­cial­ise in this area and are mem­bers of the rel­ev­ant na­tion­al and in­ter­na­tion­al as­so­ci­ations and work­ing parties.Loc­al and in­ter­na­tion­alWe can provide our ad­vice, both for loc­al and in­ter­na­tion­al mar­kets, in the fol­low­ing areas:Brands, trade­marks and passing-offIP Lit­ig­a­tionPat­ents, util­ity mod­elsKnow-how and con­fid­en­tial in­form­a­tionIn­dus­tri­al design rightsCopy­rightCom­pet­i­tion lawAnti-coun­ter­feit­ing and anti-pir­acyCus­toms pro­ceed­ings, par­al­lel im­port- and grey mar­ket is­suesCon­tracts for the pro­tec­tion, man­age­ment and ex­ploit­a­tion of IP rightsin­clud­ing stra­tegic al­li­ances, tech­no­logy trans­fer, li­cens­ing, fran­chising,mer­chand­ising and R&D agree­mentsEval­u­ation of IP port­fo­li­os in the course of due di­li­gence pro­ceed­ingsData­bases and data pro­tec­tionRe­cog­nised lead­ers and re­la­tion­ship driv­enWe are In­tel­lec­tu­al Prop­erty ex­perts – our highly re­garded team of more than 65 part­ners and over 80 as­so­ci­ates has a wealth of IP ex­per­i­ence and our law­yers are re­cog­nised by all of the leg­al dir­ect­or­ies.We are highly in­volved in the de­vel­op­ment of In­tel­lec­tu­al Prop­erty law and policy – we are mem­bers of the In­ter­na­tion­al Trade Mark As­so­ci­ation (IN­TA) and serve on a num­ber of IN­TA com­mit­tees. We are also mem­bers of and play an act­ive role in PT­MG, Marques, ITech­Law, AIPLA and AIPPI.We are re­cog­nised in­dustry sec­tor lead­ers – we fo­cus our In­tel­lec­tu­al Prop­erty prac­tice around nine in­dustry sec­tors in­clud­ing:Auto­mot­iveCon­sumer ProductsEn­ergyLifes­ci­encesMech­an­ic­al En­gin­eer­ingTech­no­logy, Me­dia and Com­mu­nic­a­tions
CMS Ex­pert Guides
Easy ac­cess to ex­pert ad­vice that’s rel­ev­ant to you

Feed

Show only
31 January 2020
Con­sumer Products News­let­ter
In­tel­lec­tu­al Prop­erty and Un­fair Com­pet­i­tion law
22 April 2020
CMS Ex­pert Guide to COV­ID-19's Im­pact on IP Leg­al Tim­ings
As in all as­pects of busi­ness, COV­ID-19 is im­pact­ing the world of IP and the po­s­i­tion is con­stantly chan­ging. To help you pri­or­it­ise and plan, the Glob­al IP prac­tice at CMS has put to­geth­er an over­view of COV­ID-19's cur­rent im­pact on pro­ced­ur­al timetables be­fore courts, na­tion­al in­tel­lec­tu­al prop­erty of­fices and key in­ter­na­tion­al IP in­sti­tu­tions.
26 May 2020
European Com­mis­sion must ad­dress in­tel­lec­tu­al prop­erty and AI
The Com­mit­tee on Leg­al Af­fairs (JURI) of the European Par­lia­ment has pub­lished three draft re­ports re­lat­ing to ar­ti­fi­cial in­tel­li­gence (AI). This note is about the draft re­port on in­tel­lec­tu­al prop­erty...
August 2019
How block­chain will re­volu­tion­ise the gam­ing in­dustry
30 April 2019
CMS Ex­pert Guide to Post BEPS In­tel­lec­tu­al Prop­erty Tax­a­tion
Com­par­is­on between the dif­fer­ent IP boxes
26 May 2020
European Pat­ent Of­fice COV­ID-19 pro­vi­sions - as at 25 May 2020
The EPO has re­cently is­sued fur­ther in­form­a­tion re­gard­ing or­al pro­ceed­ings be­fore ex­am­in­a­tion and op­pos­i­tion di­vi­sions and be­fore the Boards of Ap­peal. This art­icle sum­mar­ises all of the EPO’s COV­ID-19...
August 2019
Game­play on-the-move
What's next for mo­bile es­ports?
05 May 2020
European Pat­ent Of­fice (EPO) COV­ID-19 pro­vi­sions – as at 5 May 2020
The EPO has now is­sued a fur­ther guid­ance no­tice re­gard­ing its dead­lines in light of the on­go­ing coronavir­us situ­ation, which re­places the pre­vi­ous no­tice dated 16 April 2020 and which will be pub­lished...
August 2019
Avoid­ing ugly head­lines
Com­pli­ance in es­ports
30 April 2020
COV­ID-19 - EUIPO ex­tends dead­lines
The EUIPO yes­ter­day ex­ten­ded time lim­its which are due to ex­pire between Fri­day, 1 May 2020 and Sunday, 17 May 2020 to Monday, 18 May 2020. This fol­lows the earli­er ex­ten­sion of time lim­its un­til 1 May...
19 August 2019
Will fans pay per view for ex­clus­ive es­ports con­tent?
27 March 2020
Man­aging clin­ic­al tri­als un­der COV­ID-19: New EU guid­ance is­sued for spon­sors...
The COV­ID-19 pan­dem­ic has had a dra­mat­ic im­pact on European health sys­tems, whose pri­or­ity first and fore­most is the treat­ment of pa­tients suf­fer­ing from this dis­ease both in the in-pa­tient and out-pa­tient...